At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 521 enrolled
Drug / intervention
Epirubicin +2 moredrug
Likely dose
Epirubicin 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old
In Brief
A Phase 3 clinical trial evaluating Epirubicin, Cyclophosphamide, and 1 other intervention for Breast Neoplasms. Completed, enrolled 521 participants across 1 site.
Detailed Summary
Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedDec 2009
Primary CompletionJan 2016
Study CompletionDec 2016
TodayJul 2026
First PostedDec 4, 2009
Enrollment StartDec 1, 2009
Primary CompletionJan 1, 2016
Study CompletionDec 23, 2016
TodayJul 1, 2026
Enrollment to primary: 6.1 yearsPosted 16.6 years ago
Interventions
Epirubicindrug
75 mg/m2 every-3-week for four cycles
Cyclophosphamidedrug
600 mg/m2 every-3-week for four cycles
Paclitaxeldrug
175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks